PDF herunterladen
Aktuelle Dermatologie 2015; 41(03): 77-80
DOI: 10.1055/s-0034-1377790
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Entwicklungen in der Prävention und Therapie des Hand- und Fußsyndroms

Recent Developments in the Prevention and Treatment of Palmar Plantar Erythrodysesthesia
S. Jung
1   Klinik für Dermatologie, Venerologie und Allergologie, Center of Experimental and Applied Cutaneous Physiology, Charité – Universitätsmedizin Berlin
,
J. Sehouli
2   Klinik für Gynäkologie und Geburtshilfe, Charité – Universitätsmedizin Berlin
,
R. Chekerov
2   Klinik für Gynäkologie und Geburtshilfe, Charité – Universitätsmedizin Berlin
,
A. Patzelt
1   Klinik für Dermatologie, Venerologie und Allergologie, Center of Experimental and Applied Cutaneous Physiology, Charité – Universitätsmedizin Berlin
,
F. Knorr
1   Klinik für Dermatologie, Venerologie und Allergologie, Center of Experimental and Applied Cutaneous Physiology, Charité – Universitätsmedizin Berlin
,
J. Lademann
1   Klinik für Dermatologie, Venerologie und Allergologie, Center of Experimental and Applied Cutaneous Physiology, Charité – Universitätsmedizin Berlin
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. März 2015 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Das Hand- und Fußsyndrom, auch bekannt als palmoplantare Erythrodysästhesie, beschreibt eine kutane Nebenwirkung unter einer Reihe von Chemotherapeutika, deren Symptome unter Umständen zum Therapieabbruch und zu der Notwendigkeit von zusätzlichen medizinischen Maßnahmen führen können. Die zumeist palmar und plantar auftretenden, teils schmerzhaften, erythematösen Hautveränderungen haben, je nach Ausprägung, eine teils erhebliche Einschränkung der Lebensqualität betroffener Patienten zur Folge. Da die Symptome des Hand- und Fußsyndroms unter einer Chemotherapie in den meisten Fällen einen progredienten Verlauf zeigen, stellte die Dosismodifikation bzw. eine Pausierung oder gar ein Abbruch der Chemotherapie bisher häufig die einzige effiziente Therapiemaßnahme dar. Aktuelle Studien deuten jedoch darauf hin, dass die begleitende topische Applikation von hoch konzentrierten, kombinierten Antioxidantien eine effektive Präventions- und Behandlungsstrategie des Hand- und Fußsyndroms darstellt.

Abstract

The hand-foot syndrome, also known as palmoplantar erythrodysesthesia (PPE), describes a chemotherapy-associated cutaneous side effect that can lead to discontinuation or postponement of the chemotherapy or require additional medical treatment. Affected patients often present painful erythema, edema or profound skin lesions which are mostly limited to the palms of the hands and soles of the feet. These skin lesions can result in a considerable limitation of the quality of life in affected patients. Since PPE symptoms mostly show a progressive course under ongoing chemotherapeutical treatment, so far the dose reduction, postponement or even discontinuation of the scheduled chemotherapy has often been the only effective therapeutic option. Recent studies, however, suggest that the topical application of highly concentrated combined antioxidants can represent an effective prevention and treatment strategy of hand-foot syndrome.

 

  • Literatur

  • 1 Hackbarth M, Haas N, Fotopoulou C et al. Chemotherapy-induced dermatological toxicity: Frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Supportive Care in Cancer 2007; 16: 267-273
    PubMedGoogle Scholar
  • 2 Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (ppe): A literature review with commentary on experience in a cancer centre. European Journal of Oncology Nursing 2007; 11: 238-246
    CrossrefPubMedGoogle Scholar
  • 3 Lorusso D, Di Stefano A, Carone V et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Annals of Oncology 2007; 18: 1159-1164
    CrossrefPubMedGoogle Scholar
  • 4 Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-1047
    CrossrefPubMedGoogle Scholar
  • 5 von Moos R, Thuerlimann BJ, Aapro M et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur J Cancer 2008; 44: 781-790
    CrossrefPubMedGoogle Scholar
  • 6 Gerbrecht BM. Current canadian experience with capecitabine: Partnering with patients to optimize therapy. Cancer Nurs 2003; 26: 161-167
    CrossrefPubMedGoogle Scholar
  • 7 National Cancer Institute. Common terminology criteria for adverse events v4.0. NCI, NIH, DHHS 2009; NIH publication +09-7473
    PubMedGoogle Scholar
  • 8 Blum JL, Jones SE, Buzdar AU et al. Multicenter phase ii study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493
    PubMedGoogle Scholar
  • 9 Farr KP, Safwat A. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011; 4: 229-235
    CrossrefPubMedGoogle Scholar
  • 10 Degen A, Alter M, Schenck F et al. The hand-foot-syndrome associated with medical tumor therapy – classification and management. J Dtsch Dermatol Ges 2010; 8: 652-661
    PubMedGoogle Scholar
  • 11 Akoglu G. Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes. Indian J Pharmacol 2014; 46: 225-227
    CrossrefPubMedGoogle Scholar
  • 12 Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Meta-analysis group in cancer. J Clin Oncol 1998; 16: 3537-3541
    PubMedGoogle Scholar
  • 13 Keohan M, D’Adamo D, Qin L et al. Analysis of toxicity in a phase ii study of sorafenib in soft tissue sarcoma (sts). Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2007; Meeting Abstracts 25 (18 Supplement): 10061 -- ASCO
    PubMedGoogle Scholar
  • 14 Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase i trials in patients with advanced refractory solid tumors. Oncologist 2007; 12: 426-437
    CrossrefPubMedGoogle Scholar
  • 15 Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology 2009; 77: 257-271
    CrossrefPubMedGoogle Scholar
  • 16 Sibaud V, Delord JP, Chevreau C. Sorafenib-induced hand-foot skin reaction: A koebner phenomenon?. Target Oncol 2009; 4: 307-310
    CrossrefPubMedGoogle Scholar
  • 17 Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-1051
    CrossrefPubMedGoogle Scholar
  • 18 Hueso L, Sanmartin O, Nagore E et al. Chemotherapy-induced acral erythema: A clinical and histopathologic study of 44 cases. Actas Dermosifiliogr 2008; 99: 281-290
    CrossrefPubMedGoogle Scholar
  • 19 Gordon KB, Tajuddin A, Guitart J et al. Hand-foot syndrome-associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169-2173
    CrossrefPubMedGoogle Scholar
  • 20 Fitzpatrick JE, Hood AF. Histopathologic reactions to chemotherapeutic agents. Adv Dermatol 1988; 3: 161-183
    PubMedGoogle Scholar
  • 21 Beard JS, Smith KJ, Skelton HG. Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. J Am Acad Dermatol 1993; 29: 325-330
    CrossrefPubMedGoogle Scholar
  • 22 Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002; 16: 31-37
    PubMedGoogle Scholar
  • 23 Lademann J, Martschick A, Kluschke F et al. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. Skin Pharmacol Physiol 2014; 27: 66-70
    CrossrefPubMedGoogle Scholar
  • 24 Martschick A, Sehouli J, Patzelt A et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 2009; 29: 2307-2313
    PubMedGoogle Scholar
  • 25 Jacobi U, Waibler E, Schulze P et al. Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome?. Ann Oncol 2005; 16: 1210-1211
    CrossrefPubMedGoogle Scholar
  • 26 Yokomichi N, Nagasawa T, Coler-Reilly A et al. Pathogenesis of hand-foot syndrome induced by peg-modified liposomal doxorubicin. Hum Cell 2013; 26: 8-18
    CrossrefPubMedGoogle Scholar
  • 27 Lademann J, Rowert-Huber HJ, Haas N et al. Palmoplantar erythrodysesthesia-like skin symptoms in patients under various chemotherapeutics: Preventive and therapeutic options. Skin Pharmacol Physiol 2014; 27: 228-232
    CrossrefPubMedGoogle Scholar